Form 4: Illumina Divests Significant GRAIL Stake

Illumina, Inc. has completed the sale of 1,000,000 shares of GRAIL, Inc. common stock at $79.85 per share, reducing its beneficial ownership below 10%.

Summary

• Illumina, Inc. reported the sale of 1,000,000 shares of GRAIL, Inc. common stock.
• The transaction occurred on November 17, 2025, at a price of $79.85 per share.
• Following this sale, Illumina's beneficial ownership in GRAIL, Inc. stands at 3,502,126 shares.
• Illumina is no longer a 10% beneficial owner of GRAIL, Inc., marking this as an exit filing.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive for Illumina as it successfully executes a planned divestment, generating significant cash. For GRAIL, the exit of a major shareholder could be seen as neutral to slightly negative, depending on market interpretation of the underlying reasons (regulatory vs. strategic). Overall, the execution of a pre-planned transaction is a positive for the reporting entity.

Positives

• Illumina successfully executed a planned divestment of a significant portion of its GRAIL stake.
• The sale generated proceeds of approximately $79.85 million for Illumina.
• The transaction was conducted under a Rule 10b5-1(c) plan, indicating a pre-arranged, orderly sale.

Negatives

• The sale by a major shareholder like Illumina could exert downward pressure on GRAIL's stock price.
• Illumina's reduced stake might be perceived as a lack of long-term confidence in GRAIL by some investors, although it is part of a regulatory-driven divestment.

Future Outlook

The filing indicates Illumina is no longer a 10% beneficial owner of GRAIL, Inc., suggesting a continued reduction or complete divestment of its remaining stake in the future, consistent with regulatory mandates.

Management Comments

• Rob Maynes, Vice President, Legal and Assistant Secretary, signed the filing on behalf of Illumina, Inc.

Industry Context

This transaction is a continuation of Illumina's strategic divestment of GRAIL, Inc., following regulatory challenges and mandates related to its acquisition of GRAIL. The divestment process has been a significant event in the diagnostics and life sciences industry, impacting both companies' strategic directions and market perceptions.

Related Party Transactions

• Illumina, Inc. was a 10% owner of GRAIL, Inc. prior to this transaction, making the sale of shares a transaction by a related party (a significant shareholder).

Stakeholder Impact

• **Illumina Shareholders**: Benefit from the cash proceeds of the sale and the ongoing execution of the GRAIL divestment strategy, which aims to resolve regulatory issues.
• **GRAIL Shareholders**: May experience short-term stock price volatility due to the large block sale by a significant shareholder. The long-term impact depends on how the market perceives Illumina's full exit.

Next Steps

• Illumina will likely continue to manage its remaining stake in GRAIL, Inc. as part of its ongoing divestment strategy, potentially leading to further sales until full separation is achieved.

Key Dates

Keywords

Illumina, GRAIL, Form 4, Insider Sale, Stock Sale, Beneficial Ownership, Divestment, 10b5-1 Plan, Biotech, Healthcare